Hims & Hers Health, Inc. $HIMS Shares Sold by Legal & General Group Plc

Legal & General Group Plc lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 15.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 324,175 shares of the company’s stock after selling 60,322 shares during the quarter. Legal & General Group Plc’s holdings in Hims & Hers Health were worth $10,526,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in HIMS. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. Invesco Ltd. lifted its position in Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after purchasing an additional 1,600,004 shares during the period. Clear Street Group Inc. acquired a new stake in Hims & Hers Health in the third quarter valued at about $87,372,000. Vanguard Group Inc. lifted its position in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the period. Finally, BIT Capital GmbH lifted its position in Hims & Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 0.1%

Shares of Hims & Hers Health stock opened at $27.49 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The stock has a market cap of $6.36 billion, a PE ratio of -305.46, a price-to-earnings-growth ratio of 53.38 and a beta of 2.37. The company has a 50-day moving average of $24.37 and a two-hundred day moving average of $27.15.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same period last year, the business posted $0.20 earnings per share. The company’s quarterly revenue was up 3.8% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers completed its acquisition of Eucalyptus, expanding into Australia, Canada, Germany, and Japan and strengthening its global telehealth and weight-management footprint. Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
• Positive Sentiment: The Eucalyptus deal supports Hims & Hers’ long-term growth story by adding established brands and clinical infrastructure in key international markets. HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks
• Neutral Sentiment: Investors are re-evaluating Hims & Hers’ valuation after sharp recent swings, with the stock showing strong short-term gains but weaker year-to-date performance. Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings
• Negative Sentiment: U.S. Senator Jim Banks is pressing the FDA to review Hims & Hers’ GLP-1 advertising, pricing, and subscription practices, adding new political and regulatory risk around a key growth area. Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story
• Negative Sentiment: One analyst warned that GLP-1 profitability could face pressure, which may weigh on investor confidence despite the company’s growth initiatives. HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks

Insider Buying and Selling

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David B. Wells bought 48,400 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was bought at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This represents a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 212,807 shares of company stock valued at $5,473,644 in the last 90 days. 11.76% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent analyst reports. Morgan Stanley reduced their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Barclays raised their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Truist Financial raised their price objective on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. Finally, Evercore set a $24.00 target price on shares of Hims & Hers Health in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.70.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.